BioNexus Gene Lab Corp. Reports 96.63% Revenue Decline and $286,451 Net Loss for Quarter Ending June 30, 2026

BioNexus Gene Lab Corp. reported significant financial challenges in its latest 10-Q filing for the quarter ending June 30, 2026. The company generated total revenue of $76,156 for the three-month period, a stark decline of 96.63% compared to $2,260,253 in the same quarter of the previous year. For the six-month period, revenue fell to $98,998 from $4,397,328, marking a 97.75% decrease. The substantial drop in revenue is attributed primarily to reduced sales volumes at Chemrex Corporation, the company’s subsidiary focused on industrial chemicals, and lower client referrals for genomic screening services from MRNA Scientific Sdn. Bhd.

The company's net loss for the quarter was $286,451, a decrease from a loss of $616,172 in the prior year, while the six-month net loss was $830,026 compared to $1,239,499 in the same period last year. The reduction in losses is partly due to lower operating expenses, which totaled $416,383 for the three-month period, down from $1,188,776 in the previous year. The company has also seen a decrease in its accumulated deficit, which rose to $7,257,253 as of June 30, 2026, compared to $6,427,227 at the end of the previous fiscal year.

Operationally, BioNexus has been focusing on strategic developments, including the commercialization of the VitaGuard™ minimal residual disease platform in partnership with Fidelion Diagnostics. The company entered into an Intellectual Property License Agreement with Fidelion, granting exclusive rights to the platform in the ASEAN region. However, as of the reporting date, VitaGuard had not yet begun generating revenue. The company is also modernizing its blood-based genomic screening platform through GeneMatrix Systems, with an initial release targeted for the third quarter of 2026.

In terms of liquidity, BioNexus reported cash and cash equivalents of $2,391,945 as of June 30, 2026, down from $2,486,383 at the beginning of the year. The company’s total liquidity, which includes trade receivables, was approximately $3.5 million. Management believes that current cash reserves, along with potential financing from its $20 million at-the-market program, will be sufficient to support operations for at least the next 12 months. However, the company continues to evaluate capital-raising alternatives to enhance its liquidity position.

Looking ahead, BioNexus aims to stabilize its operations and improve its financial performance by focusing on strategic investments and partnerships. The company is also addressing internal control weaknesses identified in its Chemrex subsidiary, implementing a remediation plan to enhance governance and compliance. Despite the current challenges, management remains optimistic about future growth opportunities, particularly in the biotech sector, as it continues to refine its operational strategies and explore new market avenues.